Treatment of toxic epidermal necrolysis with the combination of infliximab and high-dose intravenous immunoglobulin.
Dermatology
; 224(2): 134-9, 2012.
Article
em En
| MEDLINE
| ID: mdl-22572593
ABSTRACT
BACKGROUND:
Therapeutic evidence for toxic epidermal necrolysis (TEN) is indicative for high-dose intravenous immunoglobulin yet inconclusive for corticosteroids.OBJECTIVE:
To describe the combination of corticosteroids, infliximab and a high-dose intravenous immunoglobulin course for TEN. PATIENTS ANDMETHODS:
In three patients (SCORTEN survival probabilities 41.7%, 64.2%, 41.7%) disease control was evaluated by (a) employing quantitative image analysis to measure progression of skin detachment and (b) patients' outcome (complete re-epithelization). Published cases of TEN treatments with infliximab were retrieved from PubMed.RESULTS:
Within 48 h skin disease progression was arrested in all patients. Two patients were discharged after 3 weeks without any sequels from skin or conjunctivae. One patient passed away on the ninth day, however with noticeably improved skin (mortality rate 33% observed vs. 50% expected). A PubMed search retrieved five TEN patients treated successfully with infliximab.CONCLUSION:
The described combination presents a feasible therapeutic alternative for TEN that warrants further evaluation.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Síndrome de Stevens-Johnson
/
Imunoglobulinas Intravenosas
/
Fármacos Dermatológicos
/
Fatores Imunológicos
/
Anticorpos Monoclonais
Limite:
Aged
/
Aged80
/
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
2012
Tipo de documento:
Article